ATRA

Atara Biotherapeutics Inc

9.16

Oct 20 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: CRBU ALLO TVGN CLLS MRKR TCRX ACET FATE NKTX IPSC

Index	-
Market Cap	91.95M
Enterprise Value	133.50M
Income	-16.69M
Sales	6.19M
Book/sh	-3.92
Cash/sh	0.98
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	14
IPO	Oct 16, 2014

P/E	-
Forward P/E	9.73
PEG	-
P/S	14.85
P/B	-
P/C	9.32
P/FCF	-
EV/EBITDA	-
EV/Sales	21.57
Quick Ratio	1.98
Current Ratio	1.98
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-1.40
EPS next Y	0.94
EPS next Q	-0.13
EPS this Y	-126.90%
EPS next Y	236.15%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	23.85% -
EPS Y/Y TTM	-253.97%
Sales Y/Y TTM	-96.72%
EPS Q/Q	-265.86%
Sales Q/Q	-96.42%
Earnings	Aug 12 AMC
EPS/Sales Surpr.	-1.59% 14.55%

Insider Own	30.97%
Insider Trans	10.11%
Inst Own	48.12%
Inst Trans	-2.19%
ROA	-57.62%
ROE	-
ROIC	-135.76%
Gross Margin	91.38%
Oper. Margin	-238.73%
Profit Margin	-269.42%
SMA20	1.11%
SMA50	-0.74%
SMA200	17.53%
Trades

Shs Outstand	9.44M
Shs Float	6.93M
Short Float	4.64%
Short Ratio	7.02
Short Interest	0.32M
52W High	19.15 -52.15%
52W Low	3.92 133.67%
Volatility	6.39% 7.54%
ATR (14)	0.65
RSI (14)	49.18
Beta	0.29
Rel Volume	0.00
Avg Volume	45.83K
Volume	0

Perf Week	-1.56%
Perf Month	-2.35%
Perf Quarter	12.74%
Perf Half Y	83.57%
Perf YTD	-49.36%
Perf Year	-42.89%
Perf 3Y	-73.26%
Perf 5Y	-97.67%
Perf 10Y	-97.58%
Recom	1.50
Target Price	13.67
Prev Close	9.16
Price	9.16
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-08-26	Upgrade	Canaccord Genuity	Hold → Buy	$13
Jan-13-26	Downgrade	Canaccord Genuity	Buy → Hold	$6
Nov-09-23	Downgrade	Mizuho	Buy → Neutral	$31 → $1
Nov-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-09-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Downgrade	Citigroup	Neutral → Sell	$8 → $3
Jul-13-22	Downgrade	Stifel	Buy → Hold	$16 → $5
Jul-13-22	Downgrade	JP Morgan	Overweight → Neutral	$10
May-10-22	Downgrade	Citigroup	Buy → Neutral	$15 → $8
May-13-21	Upgrade	JP Morgan	Neutral → Overweight	$23 → $29
Dec-09-20	Downgrade	Citigroup	Buy → Neutral	$20 → $27
Dec-08-20	Reiterated	H.C. Wainwright	Buy	$28 → $31
Nov-10-20	Reiterated	H.C. Wainwright	Buy	$26 → $28
Jun-30-20	Initiated	Evercore ISI	Outperform
Jun-15-20	Initiated	H.C. Wainwright	Buy	$25
Apr-23-20	Upgrade	Citigroup	Neutral → Buy	$14
Nov-08-19	Downgrade	JP Morgan	Overweight → Neutral	$43 → $22
Sep-27-19	Downgrade	Goldman	Neutral → Sell	$14 → $9
Sep-16-19	Downgrade	Jefferies	Buy → Hold	$32 → $15
Jun-04-19	Upgrade	Citigroup	Sell → Neutral	$23 → $24

Show Previous Ratings

Oct-14-26 08:05AM	Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration (Business Wire)
Sep-30-26 08:05AM	Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration (Business Wire) +5.59%
Aug-12-26 04:10PM	Atara Biotherapeutics: Q2 Earnings Snapshot (Associated Press) -7.75%
04:05PM	Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress (Business Wire)
Jun-12-26 04:00PM	Atara Biotherapeutics Announces Changes to Its Board of Directors (Business Wire)
09:00AM	Loading…
May-20-26 09:00AM	Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights - ATRA (PR Newswire)
May-12-26 04:40PM	Atara Biotherapeutics: Q1 Earnings Snapshot (Associated Press) +11.73% +6.83%
04:05PM	Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress (Business Wire)
May-07-26 11:03AM	FDA Resubmission Path for Tab-cel Keeps Ataras (ATRA) Regulatory Timeline Alive (InvestorsHub) +92.82%
10:30AM	BC-Most Active Stocks (Associated Press)
08:05AM	Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel (Business Wire)
Apr-16-26 06:10PM	ATRA Stockholders Have Rights - If You Lost Money Investing in Atara Biotherapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses (PR Newswire)
Apr-01-26 09:00AM	Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights - ATRA (PR Newswire) +9.30%
Mar-26-26 07:30AM	Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights ATRA (Business Wire) -5.04%
Mar-16-26 04:35PM	Atara Biotherapeutics: Q4 Earnings Snapshot (Associated Press Finance) -9.69% -10.90%
04:05PM	Loading…
04:05PM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress (Business Wire)
Mar-12-26 08:05AM	Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel (Business Wire) +10.75%
Mar-03-26 08:05AM	Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel (Business Wire) +10.39%
06:52AM	Pierre Fabre seeks to revive US approval chances for spurned cell therapy (BioPharma Dive)
Feb-23-26 08:00AM	Atara Biotherapeutics Provides a Business Update (Business Wire)
Jan-12-26 11:06AM	FDA Rejects Atara Biotherapeutics' Cell Therapy Again, Stock Sinks (Benzinga) -56.99%
08:00AM	Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO (tabelecleucel) (Business Wire)
06:24AM	AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations (BioPharma Dive)
Nov-12-25 09:11AM	Atara Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
09:00AM	Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress (Business Wire)
Nov-10-25 08:45AM	Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-07-25 06:45AM	Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains? (Zacks)
Nov-06-25 06:10PM	Pacira (PCRX) Tops Q3 Earnings Estimates (Zacks) +9.95%
Nov-05-25 06:25PM	Adma Biologics (ADMA) Q3 Earnings Match Estimates (Zacks) -12.53%
Nov-03-25 09:00AM	Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) (PR Newswire) -6.73%
09:28AM	Loading…
Sep-25-25 09:28AM	Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock? (Zacks)
Sep-03-25 06:00PM	Atara Biotherapeutics Announces Changes to Its Board of Directors (Business Wire)
Aug-19-25 05:00AM	In cell therapy, cost is a hot issue. The industry might need a cold solution. (Pharma Voice)
Aug-11-25 05:53PM	Atara Biotherapeutics: Q2 Earnings Snapshot (Associated Press Finance) -5.80% +11.82%
04:01PM	Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress (Business Wire)
Jul-24-25 08:57AM	Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) (PR Newswire)
08:00AM	Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Business Wire)
06:55AM	Rocket lays off staff; Abivax capitalizes on immune drug data (BioPharma Dive)
Jul-15-25 08:00AM	Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. (PR Newswire)
06:31AM	Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug (BioPharma Dive)
Jul-14-25 08:00AM	Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel) (Business Wire)
May-16-25 08:50PM	Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors (Business Wire) -10.12%
May-15-25 08:58AM	Atara Biotherapeutics: Q1 Earnings Snapshot (Associated Press Finance) +15.13%
08:35AM	Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress (Business Wire)
08:30AM	Atara Biotherapeutics Announces Pricing of $16Million Offering (Business Wire)
May-14-25 08:25AM	Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-13-25 09:10AM	CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-05-25 05:06PM	Atara Biotherapeutics Provides Regulatory Updates on EBVALLO (tabelecleucel) (Business Wire) -7.29% +5.79%
Apr-10-25 08:52AM	Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus (Zacks) -10.02%
Mar-13-25 12:00PM	Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Mar-07-25 05:10PM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -10.72%
04:16PM	Atara Biotherapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress (Business Wire)
Feb-14-25 09:55AM	Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet (Zacks)
08:11AM	Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws (PR Newswire)
Feb-07-25 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.95%
Jan-22-25 05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive) +13.88%
Jan-21-25 01:11PM	FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs (Benzinga) -7.91%
07:30AM	Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO (tabelecleucel) and ATA3219 (Business Wire)
Jan-17-25 07:00AM	Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs (BioPharma Dive) -16.09%
Jan-16-25 12:28PM	Atara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO Application (GuruFocus.com) -40.50%
08:30AM	Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel) (Business Wire)
Jan-02-25 12:00PM	Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why (Zacks) +6.39%
Dec-04-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now (GlobeNewswire)
Dec-03-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now (GlobeNewswire)
Nov-27-24 04:01PM	Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-13-24 04:01PM	Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference (Business Wire) +22.19% -10.45%
Nov-12-24 05:15PM	Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:13PM	Atara Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress (Business Wire)
Nov-05-24 04:01PM	Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (Business Wire) -11.61%
Oct-15-24 12:00PM	Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know (Zacks)
Oct-04-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.81%
Sep-30-24 03:16AM	After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? (Pharma Voice)
Sep-13-24 07:02PM	Redmile Group, LLC Expands Stake in Atara Biotherapeutics Inc (GuruFocus.com) +20.30% -11.52%
Sep-06-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.30% -5.28%
Sep-04-24 04:01PM	Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) +32.89% +10.50%
Sep-03-24 04:16PM	Atara Biotherapeutics Announces $36 Million Registered Direct Offering (Business Wire) -10.39%
Aug-12-24 06:10PM	Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
05:07PM	Atara Biotherapeutics: Q2 Earnings Snapshot (Associated Press Finance)
05:00PM	Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update (Business Wire)
Aug-07-24 04:01PM	Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire) -9.79%
Jul-19-24 06:12AM	US FDA grants priority review for Pierre Fabres EBV+ PTLD (Pharmaceutical Technology)
Jul-17-24 04:13PM	FDA priority review advances Ataras tabelecleucel for viral infection (Pharmaceutical Technology) -12.82%
09:00AM	Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Business Wire)
07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire) +9.95%
Jul-15-24 12:00PM	All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy (Zacks) +6.59%
Jul-05-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.39%
Jul-03-24 07:57PM	Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum (Business Wire)
Jun-21-24 04:01PM	Atara Biotherapeutics Ebvallo (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases (Business Wire) -7.53%
Jun-17-24 08:00AM	Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split (Business Wire) -16.93%
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire) +7.68%
Jun-07-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.08%
Jun-05-24 04:01PM	Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-29-24 04:01PM	Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting (Business Wire) -8.42%
May-20-24 11:57AM	Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise (MT Newswires) +16.39%
09:25AM	Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA (Business Wire)
May-09-24 10:57PM	ATRA Stock Earnings: Atara Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cherry Brian N	Director	Sep 04 '26	Buy	9.60	104,166	999,994	166,486	Sep 04 06:20 PM
Nguyen AnhCo	Director	Aug 17 '26	Proposed Sale	8.36	5,062	42,318		Aug 26 07:47 PM
Nguyen AnhCo	President and CEO	Aug 17 '26	Sale	8.08	5,062	40,883	132,775	Aug 26 07:45 PM
Nguyen AnhCo	President and CEO	May 18 '26	Sale	9.13	5,241	47,845	137,837	May 20 05:24 PM
Grant-Huerta Yanina	Chief Accounting Officer	May 18 '26	Sale	9.13	2,414	22,036	49,636	May 20 05:24 PM
Nguyen AnhCo	Director	May 18 '26	Proposed Sale	10.48	5,981	62,681		May 18 04:45 PM
Grant-Huerta Yanina	Officer	May 18 '26	Proposed Sale	10.48	2,754	28,862		May 18 04:44 PM
Panacea Innovation Ltd	10% Owner	May 07 '26	Sale	10.10	313,446	3,165,021	1,011,000	May 11 06:45 PM
EcoR1 Capital, LLC	10% Owner	May 07 '26	Buy	9.35	507,407	4,744,255	1,552,000	May 11 05:34 PM
Panacea Innovation Ltd	10% Owner	May 07 '26	Proposed Sale	10.10	313,446	3,165,021		May 07 08:30 PM
Panacea Innovation Ltd	10% Owner	Mar 17 '26	Option Exercise	0.00	259,163	26	307,899	Mar 19 04:30 PM
Grant-Huerta Yanina	Chief Accounting Officer	Mar 02 '26	Sale	5.08	2,104	10,691	31,750	Mar 04 04:28 PM
Nguyen AnhCo	President and CEO	Mar 02 '26	Sale	5.09	2,996	15,237	61,978	Mar 04 04:28 PM
Nguyen AnhCo	Director	Mar 02 '26	Proposed Sale	5.42	3,355	18,184		Mar 02 06:25 PM
Grant-Huerta Yanina	Officer	Mar 02 '26	Proposed Sale	5.42	2,355	12,764		Mar 02 06:24 PM
Panacea Innovation Ltd	10% Owner	Jan 12 '26	Sale	6.07	80,554	489,019	1,324,446	Jan 14 09:16 PM
Panacea Innovation Ltd	10% Owner	Jan 12 '26	Proposed Sale	5.88	40,000	235,200		Jan 12 09:26 PM
Panacea Innovation Ltd	10% Owner	Nov 28 '25	Option Exercise	0.00	48,737	5	48,737	Dec 01 05:00 PM
Nguyen AnhCo	President and CEO	Nov 17 '25	Sale	13.19	2,915	38,437	64,974	Nov 19 04:55 PM
Grant-Huerta Yanina	Chief Accounting Officer	Nov 17 '25	Sale	13.19	1,804	23,788	33,454	Nov 19 04:55 PM
Nguyen AnhCo	Director	Nov 17 '25	Proposed Sale	13.76	3,346	46,041		Nov 17 05:52 PM
Grant-Huerta Yanina	Officer	Nov 17 '25	Proposed Sale	13.76	2,069	28,469		Nov 17 05:50 PM

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

PresidentDr. Anhco Nguyen Ph.D.

Interim Chief Financial OfficerMr. Kevin G. Sarney CPA

Senior Vice President of Regulatory AffairsMr. Jim Sesic

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATRA

Atara Biotherapeutics Inc

Upgrade your Finviz experience